Roche, through its partner Regeneron, confirmed on Wednesday that the US government has placed an additional order for 1.25 million doses of the combination casirivimab and imdevimab to treat patients with Covid-19.
This order, the financial aspects of which are not disclosed, brings to more than 1.5 million the number of units that will be delivered across the Atlantic.
This cocktail of antibodies has been authorized in the United States as part of an emergency procedure for newly diagnosed Covid-19 patients, at high risk, but who are not hospitalized, specifies the Basel pharmaceutical giant on Wednesday. The treatment is only authorized for the duration of the declaration of the existence of circumstances justifying the authorization of the use in emergency.
Under the new agreement, the US government will purchase up to 1.25 million finished doses of casirivimab and imdevimab by June 30, 2021. Regeneron is providing the treatment for approximately 300,000 people, bringing the total purchase potential of more than 1.5 million doses in the United States, according to the Basel pharmaceutical giant.
‘Casirivimab and imdevimab will be vitally important to help fight the pandemic if approved, and we will continue to work with regulators and governments around the world to get the drug to the widest number of people possible, ‘said Bill Anderson, CEO of Roche Pharmaceuticals, the pharmaceutical division of the Rhine giant, quoted in the statement.
Clinical trials continued ___
The efficacy and safety of casirivimab and imdevimab continue to be evaluated in clinical trials for the treatment of Covid-19 in selected inpatients and outpatients. Ongoing evaluations include the open inpatient recovery test in the UK, as well as another for the prevention of Covid-19 in household contacts of those infected.
Lower doses of casirivimab and imdevimab are also being studied with the aim of increasing the supply and bringing the therapy to more patients. To date, nearly 15,000 people have participated in clinical trials on the Regeneron cocktail.
Roche is working with Regeneron to increase the global supply of casirivimab and imdevimab, with the goal of having more than 2 million doses of treatment per year. Regeneron is responsible for the development and distribution of the treatment in the United States. Roche performs these tasks outside of the United States and works to sign potential supply agreements with governments.
Roche emphasizes its commitment with its partner to make the cocktail of antibodies available to patients with Covid-19 worldwide, if approved, and to promote access in low-income countries. and lower average through drug donations to be made in partnership with public health organizations.
The American Medicines Agency (FDA) granted an emergency authorization at the end of November for treatment with antibodies to Regeneron, tests having shown that its administration reduced hospitalizations linked to Covid-19 or emergency room visits in patients with diseases secondary or ‘comorbidities’. In early October, US President Donald Trump received this cocktail of antibodies that he had widely touted after his recovery.
These antibodies mimic what the immune system does after infection with the coronavirus, by blocking the tip of the virus that allows it to attach to and enter human cells. It is considered to be more effective during the initial phase of infection, when the antibodies still have a chance to control the invader, and not during the second phase of Covid-19, when the danger is no longer the virus itself. same but the overreaction of the immune system which attacks the lungs and other organs.
Regeneron’s antibody treatment was the second synthetic antibody treatment to receive ‘Emergency Use Clearance’ (EUA) from the FDA. A similar therapy developed by the American company Eli Lilly had already obtained this status on November 9.
Regeneron has received more than $ 450 million from the US government for its efforts to develop drugs against Covid-19.